An open-label, phase II study of patritumab deruxtecan (HER3-DXd, U3-1402) in patients (pts) with previously treated advanced/metastatic colorectal cancer (CRC).

Kanwal Pratap Singh Raghav,Takayuki Yoshino,Hiroya Taniguchi,Sabine Tejpar,Arndt Vogel,Zev A. Wainberg,Kensei Yamaguchi,Masayuki Kanai,Yali Liu,Sabeen Mekan,Geetha Pudussery,Yang Qiu,Scott Kopetz

An open-label, phase II study of patritumab deruxtecan (HER3-DXd, U3-1402) in patients (pts) with previously treated advanced/metastatic colorectal cancer (CRC).

2021

Kanwal Pratap Singh Raghav
Takayuki Yoshino
Hiroya Taniguchi
Sabine Tejpar
Arndt Vogel
Zev A. Wainberg
Kensei Yamaguchi
Masayuki Kanai
Yali Liu
Sabeen Mekan
Geetha Pudussery
Yang Qiu
Scott Kopetz

TPS157Background: Patritumab deruxtecan (HER3-DXd; U3-1402) is a novel, investigational antibody drug conjugate comprising an anti-HER3 monoclonal antibody, a tetrapeptide-based linker, and a topoi...

Keywords:

Colorectal cancer
Cancer research
Antibody-drug conjugate
Linker
open label
Phases of clinical research
Monoclonal antibody
Patritumab
Tetrapeptide
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations